Interní Med. 2015; 17(2): 83-86 [Klin Farmakol Farm. 2015;29(2):77-79]

Insulin analogs - an up-to date perspective for type 1 and type 2 diabetes

doc.MUDr.Rudolf Chlup, CSc.
Ústav fyziologie LF UP v Olomouci a II. interní klinika FNOL

This overview comprises principle data on development of the first animal insulins in 1921/22 up to present rapid and longlasting insulin

analogs. Based on several American and European trials and also on our own observations we may conclude that insulin analogs should

be considdered as first choice insulin preparations for both type 1 and type 2 diabetes mellitus.

Keywords: insulin analogs, continuous subcutaneous insulin infusion, pharmacokinetics

Published: April 10, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chlup R. Insulin analogs - an up-to date perspective for type 1 and type 2 diabetes. Interní Med. 2015;17(2):83-86.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001; 24: 69-72. Go to original source... Go to PubMed...
    2. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marrat G, Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabetes UK Diabetic Medicine 2004; 21: 171-175. Go to original source... Go to PubMed...
    3. Chapman TM, Noble S, Goa KL. Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62: 1945-1981. Go to original source... Go to PubMed...
    4. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin. Pharmacokinet. 2001; 40: 641-659. Go to original source... Go to PubMed...
    5. Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp.Clin. Endocrinol. Diabetes 2002; 110: 416-419. Go to original source...
    6. Chlup R, Zapletalová J, Seckar P, Chlupová L, Táncosová S, Reznícková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004; 148(1): 27-32. Go to original source...
    7. Chlup R, Zapletalová J, Seckar P, Malá E, Doubravová B, Táncosová S, Chlupová L, Pukowietz L, Zatloukal P. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diabetes Technol Ther. 2007; 9(3): 223-231. Go to original source... Go to PubMed...
    8. Home PD. The pharmacokinetics and pharmacodynamics of rapid acting insulin analogues and their therapeutical consequences. Diabetes Obesity and Metabolism 2012; 14: 780-788. Go to original source...
    9. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the tratment of diabetes mellitus. Journal of Diabetes 2013; 5: 482-491. Go to original source... Go to PubMed...
    10. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. The Lancet 2014; 384(9950): 1265-1272. http://dx.doi.org10.1016/S0140-6736(14)61037-0. Go to original source... Go to PubMed...
    11. Chlup R, Vaverková H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients: I. Effects on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105(Suppl2): 70-73. Go to original source...
    12. Vaverková H, Chlup R, Ficker L, Novotný D, Bartek J. Complementary insulin therapy improves blood glucoseand serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients: II. Effects on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl2): 74-77. Go to original source...
    13. Nosek L, Roggen K, Heinemann L, et al. Insulin aspart has a shorter duration of action than human insulin over a wide doserange.Diabetes Obes Metab 2013; 15: 77-83. Go to original source...
    14. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014; 2(7): 553-561. doi: 10.1016/S2213-8587(14)70073-7. Go to original source...
    15. Novo Nordisk. Summary of Product Characteristics, NovoRapid(R) (insulin aspart). Bagsvaerd: Novo Nordisk, 2004. Last update: Dec. 2012.
    16. Kerr D, Wizemann E, Senstius J, et al. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review. J Diabetes Sci Technol 2013; 7: 1595-1606. Go to original source... Go to PubMed...
    17. van Bon AC, Bode BW, Sert-Langeron C, et al. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2011; 13: 607-614. Go to original source...
    18. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, BellaireS, RabenA on behalf of the insulin aspart pregnancy study group. Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771-776. Go to original source...
    19. Heller S, McCance DR, Moghissi E, Nazeri A, Kordonouri O. Diversity in diabetes: the role of insulin aspart. Diabetes Metab Res Rev 2012; 28: 50-61. Go to original source... Go to PubMed...
    20. Pettitt D, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an Insulin Analog, Insulin Aspart, and Regular Human Insulin With No Insulin in Gestational Diabetes Mellitus. Diabetes Care 2003; 26: 183-186. Go to original source...
    21. McCance D R, Damm P, Mathiesen E R, Hod M, Kaaja R, Dunne F, Jensen LE, Mersebach H. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia 2008; 51: 2141-2143. Go to original source...
    22. Haahr H, Hövelmann U, Br?ndsted L, Adrian CL, Nosek L, Heise T. Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus. Diabetologia 2014; 57 (Suppl1): S1-S564.
    23. Heise T, Haahr H, Jensen L, Erichsen L, Hompesch M. Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus. Diabetologia 2014; 57 (Suppl1): S1-S564.
    24. Sorli C. New Developments in Insulin Therapy for Type 2 Diabetes. The American Journal of Medicine. 127 (10A).
    25. Frier BM, Russell-Jones D, HeiseT. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes, Obesity and Metabolism 2013; 11: 978-986. Go to original source...
    26. De Leeuw I, Selam J-L, Skeie S, Elte JWF, Lang H, Vague P. Insulin detemir-based used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7(1): 73-82. Go to original source...
    27. Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidemiol Drug Saf 2013. doi: 10.1002/pds.3534. Go to original source...
    28. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53: 787-800. Go to original source... Go to PubMed...
    29. Dardano A, Bianchi C, Del Prato S, Miccoli R. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes: Review. Vasc Health Risk Manag. 2014; 10: 465-475. Go to original source... Go to PubMed...
    30. Ratner R, Gough S, Mathieu CH, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B. Prospectively Planned Meta-Analysis Comparing HypoglycemiaRates of Insulin Degludec With Those of Insulin Glargine. Diabetes 2012; 61(Suppl. 1): A101. Go to original source...
    31. Buse JB, Vilsb?ll T, Thurman J, Blevins TC, Langbakke IH, B?ttcher SG, Rodbard HW. on behalf of the NN9068-3912 (DUAL-II) Trial Investigators, Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira), Diabetes Care 2014; 37: 2926-2933. Go to original source...
    32. Gough S, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB, on behalf of the NN9068-3697 (DUAL-I) trial investigators* Efficacy and safety of a fixed-ratiocombination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-na?ve patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014 Published online September 2, 2014 http://dx.doi.org/10.1016/S2213-8587(14)70174-34. Go to original source...
    33. Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care 2012; 35(11): 2140-2147. Go to original source...
    34. Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care. 2013; 36(3): 522-528. Go to original source...
    35. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.Diabetes Obes Metab 2014; 16 (4): 344-350. correction included 2014; 16(9): 877. Go to original source...
    36. Sinha VP, Choi SL, Soon DK, Mace KF, Yeo KP, Lim ST, Howey DC. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014; 54(7): 792-799. Go to original source... Go to PubMed...
    37. Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ, Cherrington AD, Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism. Diabetes. 2014; 63(2): 494-504. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.